Can Isotretinoin (Accutane) Help Some Men With Non-Obstructive Azoospermia?
Key Takeaways
Isotretinoin is being investigated as an off-label option for selected men with non-obstructive azoospermia. In one small 2025 study, motile sperm appeared in the ejaculate of 6 of 11 men with maturation arrest. This approach requires specialist supervision and is not a routine replacement for surgical sperm retrieval.
Key evidence: Jessup et al. (2025) Trial on Isotretinoin in NOA — J Assist Reprod Genet AUA/ASRM Guideline on Male Infertility Diagnosis and Management MotherToBaby (OTIS) Isotretinoin Fact Sheet
On this page
- Why is Isotretinoin Being Studied for Azoospermia?
- Video: Clinical Insights from Dr. Senai Aksoy
- The Biology: Retinoic Acid and Spermatogenesis
- Clinical Trial Evidence (Jessup et al., 2025)
- Histological Response: Who is Most Likely to Benefit?
- Treatment Protocol and Safety Monitoring
- Paternal Safety vs. Maternal Teratogenicity
- FAQ
- Sources
Why is Isotretinoin Being Studied for Azoospermia?
Isotretinoin, also known by brand names such as Accutane or Roaccutane, is an oral retinoid mainly prescribed for severe acne. Researchers are also studying its possible role in male infertility.
In non-obstructive azoospermia (NOA)—where no sperm is present in the ejaculate because sperm production is severely impaired—medical options are limited. Researchers are investigating whether altered retinoic-acid signalling contributes to arrested sperm development in some men. This remains a hypothesis under study, not a confirmed explanation for every case.
Dr. Aksoy’s Approach
I do not regard isotretinoin as routine treatment for NOA. I may discuss it as an investigational option when existing biopsy or micro-TESE material shows germ cells with maturation arrest, particularly late arrest. A history of intermittent ejaculated sperm, cryptozoospermia or rare sperm found during a previous retrieval may also support that discussion once reversible hormonal causes have been addressed.
Sertoli-cell-only histology, extensive tubular sclerosis, absent germ cells or a complete AZFa or AZFb deletion make a response biologically unlikely. I would not perform a diagnostic testicular biopsy solely to decide whether to use isotretinoin. Nor would I delay micro-TESE–ICSI when the female partner’s age or ovarian reserve makes a three-to-six-month delay clinically important. If treatment is considered, the couple should understand that it remains off-label, does not guarantee sperm retrieval or live birth, and requires structured laboratory and mental-health monitoring—preferably within an ethics-approved study.
Video: Clinical Insights from Dr. Senai Aksoy
The video is in French. Subtitles and alternative audio tracks may be available in the YouTube player settings.
The Biology: Retinoic Acid and Spermatogenesis
Spermatogenesis is a continuous, complex biological process that takes approximately 74 days in the human testis. Retinoic acid (a biologically active metabolite of vitamin A) helps regulate several important steps:
- Spermatogonial differentiation and meiotic entry: Retinoic acid induces the expression of STRA8 (Stimulated by Retinoic Acid Gene 8), allowing pre-meiotic germ cells to initiate meiosis and develop into primary spermatocytes.
- Blood–testis barrier (BTB) remodelling: Retinoids regulate tight-junction proteins between Sertoli cells, enabling developing germ cells to move from the basal to the adluminal compartment.
- Spermiation: Retinoid signalling helps coordinate the final release of mature spermatozoa from Sertoli cells into the seminiferous tubule.
An imbalance between enzymes involved in retinoic-acid production, such as ALDH1A, and breakdown, such as CYP26, could reduce retinoid signalling within the testis. Researchers are studying whether this contributes to arrested spermatogenesis in some men.
Clinical Trial Evidence (Jessup et al., 2025)
A small prospective study of oral isotretinoin in men with severe infertility was published in the Journal of Assisted Reproduction and Genetics (Jessup et al., 2025):
- Patient cohort: 30 men: 26 with non-obstructive azoospermia and 4 with intermittent cryptozoospermia. Of the men with NOA, 92% had previously undergone a testicular sperm-retrieval procedure.
- Protocol: Oral isotretinoin administered at 20 mg twice daily (40 mg/day) over 3 to 9 months.
- Primary Endpoint: Appearance of motile, ejaculated sperm sufficient for IVF with Intracytoplasmic Sperm Injection (ICSI) or cryopreservation.
- Overall results: Motile sperm appeared reliably in the ejaculate of 37% of participants (11 of 30) during treatment. This made ejaculated sperm available for ICSI in those responders.
Histological Response: Who is Most Likely to Benefit?
Histology may help identify men whose testes still contain germ cells capable of progressing through maturation. In the small 2025 study, maturation arrest was the only histological subgroup with a clearly reported response fraction (Jessup et al., 2025):
| Testicular Histopathology Pattern | Response Rate in 2025 Trial | Clinical Interpretation |
|---|---|---|
| Maturation arrest (MA) | 54% (6 of 11 men) | This subgroup had the highest observed response, but the estimate comes from only 11 men. |
| Other patterns, including hypospermatogenesis and Sertoli-cell-only syndrome | No reliable subgroup percentage established | The study is too small to support precise response percentages for these patterns. Absence of germ cells makes a biological response less plausible, but it should not be expressed as a measured rate without data. |
Treatment Protocol and Safety Monitoring
Because spermatogenesis takes approximately 74 days, with additional time for epididymal transit, the published study assessed treatment over 3–9 months. This study schedule should not be read as a standard duration for every patient.
- Baseline Testing: Semen analysis (centrifuged pellet search), hormone panel (FSH, LH, total testosterone, prolactin, estradiol), karyotype, Y-microdeletion analysis, liver transaminases (ALT/AST), and fasting lipid panel.
- Study dose: Participants in the published study received 20 mg twice daily with food. This describes the research protocol, not a self-treatment recommendation.
- Monitoring: Lipids, liver enzymes and adverse effects should be monitored at intervals chosen by the prescribing clinician according to the product information and the patient’s risk factors. Dry lips are common, but they do not prove a fertility response.
- Sperm Cryopreservation: Any newly detected ejaculated motile sperm should be cryopreserved immediately to safeguard samples for planned IVF-ICSI cycles.
Paternal Safety vs. Maternal Teratogenicity
Isotretinoin is a severe maternal teratogen when ingested by a pregnant woman. Consequently, patients frequently express deep concern about whether a father taking the medication could cause birth defects in a child.
The MotherToBaby isotretinoin fact sheet distinguishes paternal exposure from the well-established danger of maternal use during pregnancy.
Available information suggests that paternal exposures are generally unlikely to increase pregnancy risks, but direct data on men taking isotretinoin remain limited.
This distinction should not be read as proof that the drug is risk-free. Men considering off-label treatment should discuss reproductive plans, possible sexual side effects and individual precautions with the prescribing clinician.
FAQ
Is isotretinoin officially approved by regulatory agencies for azoospermia?
No. Its use in male reproductive medicine is off-label and requires supervision by a clinician experienced in male infertility.
Can isotretinoin replace surgical micro-TESE?
For some men with maturation arrest who respond by producing ejaculated sperm, micro-TESE can be avoided. However, if medical therapy fails or if SCO syndrome is present, micro-TESE remains the primary surgical retrieval option.
What are the most common side effects during treatment?
Dry lips and dry skin were common in the small 2025 study. Triglycerides or liver enzymes can also change. The prescribing clinician should set the testing schedule according to the product information, dose, treatment duration and individual risk.
How long does it take to see results?
Sperm production is slow. In the published study, treatment and semen assessments continued for 3–9 months, but only four participants remained on treatment at month 9. The evidence is therefore not strong enough to promise a usual month of response.
Related Reading
- Micro-TESE for Azoospermia: Indications, Success Rates, and Repeat Attempts
- Male Infertility Supplements: Scientific Evidence vs. Marketing Claims
- Varicocele Repair vs. IVF-ICSI: Choosing the Optimal Strategy
- Advanced Sperm Selection Techniques: IMSI, PICSI, and MACS
Sources
- Jessup CM, Amory JK, Turek PJ. Treatment with isotretinoin can improve de novo sperm production in nonobstructive azoospermia or cryptozoospermia. J Assist Reprod Genet. 2025;42(8):2793-2799. doi:10.1007/s10815-025-03567-6.
- Schlegel PN, et al. Diagnosis and treatment of infertility in men: AUA/ASRM guideline part I. Fertil Steril. 2021;115(1):54-61.
- Schlegel PN, et al. Diagnosis and treatment of infertility in men: AUA/ASRM guideline part II. Fertil Steril. 2021;115(1):62-69.
- Organization of Teratology Information Specialists (OTIS) / MotherToBaby. Isotretinoin (Accutane®).
Add as a Preferred Source on Google
You can add draksoyivf.com as one of your preferred health information sources on Google.
The content has been created by Dr. Senai Aksoy and medically approved.